Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that CD30 + status confers therapeutic sensitivity to Brentuximab vedotin, Cyclophosphamide, Dacarbazine, Dexamethasone, Doxorubicin, Etoposide in patients with Hodgkin Lymphoma.
The European Medicines Agency (EMA) has authorized brentuximab vedotin in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD) for the treatment of adult patients with previously untreated CD30+ Stage IIB with risk factors, Stage III, or Stage IV Hodgkin lymphoma (HL).
This statement is based on a regulatory approval from the European Medicines Agency:
ADCETRIS is indicated for adult patients with previously untreated CD30+ Stage IIB with risk factors, Stage III or Stage IV HL in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD).